With regards to circulating immune populations, it has been reported that the amount of circulating PD-1+ CD4+Teff cells is inversely related to OS in anti-CTLA-4 treated prostate cancer patients, with no significant difference in the case of PD-1+ CD8+ T cells [144]. Here, PDCD1 is linked to prostate carcinoma.